Neuroendocrine carcinoma of the skin+4
Not recruitingStudy of BT-001 and Pembrolizumab for Patients with Advanced Solid Tumors, Including Sarcoma, Merkel Cell Carcinoma, Melanoma, Breast, and Lung Cancer
Study of BT-001 and Pembrolizumab for Patients with Advanced Solid Tumors, Including Sarcoma, Merkel Cell Carcinoma, Melanoma, Breast, and Lung Cancer
- Disease:Neuroendocrine carcinoma of the skinTriple negative breast cancer+3
- Substances:Bt-001Pembrolizumab+1
France- Participants:18–64 years · 65+ years
- Substances:Bt-001
- Sponsor:Transgene





